Abstract
EARLY in 1962 Prof. Alexander Haddow suggested that we should test thalidomide for carcinogenicity. Accordingly, 20 male mice of the Chester Beatty stock strain were injected subcutaneously in the flank once weekly with 15-mg thalidomide suspended in 0.2 ml. arachis oil. A similar number of mice was injected weekly with arachis oil only and a further group left untreated. Injections of thalidomide were stopped at 57 weeks (total dose of thalidomide = 855 mg), but injections of arachis oil were continued for 90 weeks.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Millen, J. W., Lancet, ii, 599 (1962).
Hunter, T. A. A., Lancet, ii, 400 (1962).
Rogerson, G., Lancet, i, 691 (1962).
Bach, A., Bichel, J., and Hejgaard, J. J., Lancet, i, 1271 (1963).
Roath, S., Elves, M. W., and Israëls, M. C. G., Lancet, ii, 813 (1962).
Roath, S., Elves, M. W., and Israëls, M. C. G., Lancet, i, 249 (1963).
Lindahl-Kiessling, K., and Böök, J. A., Lancet, ii, 405 (1963).
Lüers, H., Lancet, ii, 1332 (1962).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
ROE, F., MITCHLEY, B. Thalidomide and Neoplasia. Nature 200, 1016–1017 (1963). https://doi.org/10.1038/2001016a0
Issue Date:
DOI: https://doi.org/10.1038/2001016a0
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.
